Cabozantinib (cabo) + abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): Preclinical evaluation and interim results of an investigator-sponsored phase 1 clinical study

Category Primary study
JournalCancer Research
Year 2013
This article has no abstract
Epistemonikos ID: 6d5cbd47ef395dcd1efd619045802510f4d51f2e
First added on: Feb 05, 2025